No Data
Is Weakness In Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Sunflower Pharmaceutical: Report for the third quarter of 2024
Sunflower Pharmaceutical Group (002737.SZ): The net income in the first three quarters was 0.587 billion yuan, a 31.06% year-on-year decrease.
格隆汇October 28th news | Sunflower Pharmaceutical Group (002737.SZ) announced the third quarter report for 2024, with the company achieving revenue of 2.967 billion yuan in the first three quarters, a 29.95% year-on-year decrease; net income attributable to shareholders of the listed company was 0.587 billion yuan, a 31.06% year-on-year decrease; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.46 billion yuan, a 2.05% year-on-year decrease; basic earnings per share was 1.0 yuan.
Sunflower Pharmaceutical Group (002737.SZ) released its performance for the first three quarters, with a net income of 0.587 billion yuan, a year-on-year decrease of 31.06%.
sunflower pharmaceutical group (002737.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Sunflower Pharmaceutical Group (002737.SZ): plans to invest 10 million yuan to establish Sunflower Pharmacy.
格隆汇October 24th, Sunflower Pharmaceutical Group (002737.SZ) announced that its wholly-owned subsidiary, Sunflower Pharmaceutical Group Pharmaceutical Co., Ltd., plans to invest 10 million yuan of its own funds to establish a wholly-owned subsidiary, Sunflower Pharmacy (Hubei) Co., Ltd. (preparatory). This investment aims to follow the trend of digital marketing, build an online self-operated platform, strengthen new channels, influence new customer groups, expand new volume, and establish a closed-loop management of online marketing business. It will help enhance the company's brand influence, assist in the company's model upgrade, optimize the company's channel layout, and strengthen the company's competitive advantage.
Sunflower Pharmaceutical Group (002737.SZ): The Ursodeoxycholic Acid Capsules have been accepted for market approval.
On October 14, Gelonghui reported that Sunflower Pharmaceutical Group (002737.SZ) announced that its holding subsidiary, Sunflower Pharmaceutical Group (Tangshan) Biopharmaceutical Co., Ltd. recently received the "Acceptance Notice" issued by the National Medical Products Administration for the application for registration and listing of Ursodeoxycholic Acid Capsules. The intended indications (or main functions) of the above-mentioned pharmaceutical are: (1) Gallbladder cholesterol stones must be stones that can be penetrated by X-rays, and the gallbladder contraction function must be normal; (2) Biliary stasis liver disease (such as primary biliary cirrhosis); (3) Bile reflux gastritis.
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Stock Has Fared Decently: Is the Market Following Strong Financials?No Data
No Data
